中国精神分裂症防治指南

标题: 中国精神分裂症防治指南
title: Guidelines for schizophrenia Prevention and Treatment in China
版本: 更新版
version: Updated
分类: 标准指南
classification: Standard guideline
领域: 综合
field: Comprehensive guideline
国家和地区: 中国
Country and region: China
指南使用者:
Guide users:
证据分级方法: 采用GRADE方法针对结果表的证据体质量进行评价。根据GRADE方法,将证据质量分为高、中、低、极低四个等级。在证据分级过程中,考虑五个降级因素——偏倚风险、不精确性、不一致性、间接性以及发表偏倚,和三个升级因素——效应量大、存在剂量反应关系以及可能的混杂因素被恰当处理(负偏倚)。完成证据分级后,将通过证据总结表呈现证据。 在针对每个临床问题进行证据汇总和展示时,指南制订组使用GRADEpro指南开发工具(www.gradepro.org)构建GRADE证据概要和“证据到决策”(Evidenc to decision, EtD)的框架,以总结系统评价的结果13-15。每个临床问题对应的EtD表格均包括以下内容:与干预和对照措施相关的有效性和安全性,卫生资源占用,成本效益,患者价值观和偏好,对卫生公平性的影响,可接受性和可行性的部分。
Evidence grading method: The GRADE method was used to evaluate the evidence quality of the result tables. According to the GRADE , the quality of evidence was classified into four levels: high, medium, low, and very low. Five de-escalation factors – risk of bias, imprecision, inconsistency, indirectness, and publication bias – and three escalation factors – large effect sizes, dose-response relationships, and possible confounding factors were considered as appropriate (negative bias) in the evidence grading process. Upon completion of the evidence grading, the evidence will be presented via an evidence summary table. In summarizing and presenting the evidence for each clinical question, the guideline development group used the GRADEpro guideline development tool (i.e. www.gradepro.org ), to construct a GRADE evidence summary and a framework of "evidence to decision" (EtD) to summarize the results of systematic reviews 13 – 15. The EtD tables corresponding to each clinical question include the following: Effectiveness and safety related to interventions and controls, health resource utilization, cost-effectiveness, patient values and preferences, impact on health equity, acceptability, and feasibility sections.
制定单位: 中华医学会精神医学分会
Formulating unit: Psychiatry Society of Chinese Medical Association
注册时间: 2023-03-28
Registration time:
注册编号: PREPARE-2023CN195
Registration number:
指南制订的目的:
Purpose of the guideline: